{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T09:40:08Z","timestamp":1766050808812,"version":"3.38.0"},"reference-count":50,"publisher":"National Center for Global Health and Medicine (JST)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["GHM"],"published-print":{"date-parts":[[2025,2,28]]},"DOI":"10.35772\/ghm.2024.01080","type":"journal-article","created":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T22:11:12Z","timestamp":1737756672000},"page":"13-27","source":"Crossref","is-referenced-by-count":2,"title":["Postoperative adjuvant chemotherapy in patients with gastric cancer based on the Nationwide Gastric Cancer Registry in Japan"],"prefix":"10.35772","volume":"7","author":[{"given":"Yasuhide","family":"Yamada","sequence":"first","affiliation":[{"name":"Department of Medical Research, National Center for Global Health and Medicine, Tokyo, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuyuki","family":"Seto","sequence":"additional","affiliation":[{"name":"National Cancer Center Hospital, Tokyo, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takaki","family":"Yoshikawa","sequence":"additional","affiliation":[{"name":"Department of Gastric Surgery, National Cancer Center Hospital, Tokyo, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroya","family":"Takeuchi","sequence":"additional","affiliation":[{"name":"Department of Surgery, Hamamatsu University, School of Medicine, Hamamatsu, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuko","family":"Kitagawa","sequence":"additional","affiliation":[{"name":"Department of Surgery, Keio University, School of Medicine, Tokyo, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhiro","family":"Kodera","sequence":"additional","affiliation":[{"name":"NHO Nagoya Medical Center, Nagoya, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuichiro","family":"Doki","sequence":"additional","affiliation":[{"name":"Osaka University, Osaka, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhiro","family":"Yoshida","sequence":"additional","affiliation":[{"name":"Gifu University, Gifu, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kei","family":"Muro","sequence":"additional","affiliation":[{"name":"Department of Pharmacotherapy, Aichi Cancer Center, Nagoya, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshinori","family":"Kabeya","sequence":"additional","affiliation":[{"name":"Healthcare &amp; Life Sciences, IBM Japan, Ltd, Tokyo, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ami","family":"Kamada","sequence":"additional","affiliation":[{"name":"Healthcare &amp; Life Sciences, IBM Japan, Ltd, Tokyo, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kengo","family":"Nagashima","sequence":"additional","affiliation":[{"name":"Biostatistics Unit, Clinical and Translational Research Center, Keio University Hospital, Tokyo, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiraku","family":"Kumamaru","sequence":"additional","affiliation":[{"name":"Department of Healthcare Quality Assessment, The University of Tokyo Graduate School of Medicine, Tokyo, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hisateru","family":"Tachimori","sequence":"additional","affiliation":[{"name":"Department of Health Policy and Management, Keio University School of Medicine, Tokyo, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsuru","family":"Sasako","sequence":"additional","affiliation":[{"name":"Yodogawa Christian Hospital, Osaka, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hitoshi","family":"Katai","sequence":"additional","affiliation":[{"name":"Tachikawa Hospital, Tokyo, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Konno","sequence":"additional","affiliation":[{"name":"Hamamatsu University, School of Medicine, Hamamatsu, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshihiro","family":"Kakeji","sequence":"additional","affiliation":[{"name":"Database Committee, The Japanese Society of Gastroenterological Surgery, Tokyo, Japan."},{"name":"Division of Gastrointestinal Surgery, Department of Surgery, Kobe University Graduate School of Medicine, Kobe, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"21485","reference":[{"doi-asserted-by":"crossref","unstructured":"1. Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024; 74:229-263.","key":"1","DOI":"10.3322\/caac.21834"},{"doi-asserted-by":"crossref","unstructured":"2. Thrift AP, Wenker TN, El-Serag HB. Global burden of gastric cancer: Epidemiological trends, risk factors, screening and prevention. Nat Rev Clin Oncol. 2023; 20:338-349.","key":"2","DOI":"10.1038\/s41571-023-00747-0"},{"doi-asserted-by":"crossref","unstructured":"3. Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, Furukawa H, Nakajima T, Ohashi Y, Imamura H, Higashino M, Yamamura Y, Kurita A, Arai K; ACTS-GC Group. Adjuvant chemotherapy for gastric cancer. N Engl J Med. 2007; 357:1810-1820.","key":"3","DOI":"10.1056\/NEJMoa072252"},{"doi-asserted-by":"crossref","unstructured":"4. Sasako M, Sakuramoto S, Katai H, Kinoshita T, Furukawa H, Yamaguchi T, Nashimoto A, Fujii M, Nakajima T, Ohashi Y. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer with S-1, an oral fluoropyrimidine. J Clin Oncol. 2011; 29:4387-4393.","key":"4","DOI":"10.1200\/JCO.2011.36.5908"},{"doi-asserted-by":"crossref","unstructured":"5. Yoshikawa T, Terashima M, Mizusawa J, <i>et al.<\/i> Four courses versus eight courses of adjuvant S-1 for patients with stage II gastric cancer (JCOG1104 [OPAS-1]): An open-label, phase 3, non-inferiority, randomised trial. Lancet Gastroenterol Hepatol. 2019; 4:208-216.","key":"5","DOI":"10.1016\/S2468-1253(18)30383-2"},{"doi-asserted-by":"crossref","unstructured":"6. Yoshikawa T, Terashima M, Mizusawa J, <i>et al.<\/i> 5-year follow-up results of a JCOG1104 (OPAS-1) phase III non-inferiority trial to compare 4 courses and 8 courses of S-1 adjuvant chemotherapy for pathological stage II gastric cancer. Gastric Cancer. 2024; 27:155-163.","key":"6","DOI":"10.1007\/s10120-023-01447-5"},{"doi-asserted-by":"crossref","unstructured":"7. Yoshida K, Kodera Y, Kochi M, <i>et al.<\/i> Addition of docetaxel to Oral fluoropyrimidine improves efficacy in patients with stage III gastric cancer: Interim analysis of JACCRO GC-07, a randomized controlled trial. J Clin Oncol. 2019; 37:1296-1304.","key":"7","DOI":"10.1200\/JCO.18.01138"},{"doi-asserted-by":"crossref","unstructured":"8. Kakeji Y, Yoshida K, Kodera Y, <i>et al. <\/i>Three-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 plus docetaxel versus S-1 alone in stage III gastric cancer: JACCRO GC-07. Gastric Cancer. 2022; 25:188-196.","key":"8","DOI":"10.1007\/s10120-021-01224-2"},{"doi-asserted-by":"crossref","unstructured":"9. Kodera Y, Yoshida K, Kochi M, Sano T, Ichikawa W, Kakeji Y, Sunakawa Y, Takeuchi M, Fujii M. Addition of docetaxel to S-1 results in significantly superior 5-year survival outcomes in Stage III gastric cancer: A final report of the JACCRO GC-07 study. Gastric Cancer. 2023; 26:1063-1068.","key":"9","DOI":"10.1007\/s10120-023-01419-9"},{"doi-asserted-by":"crossref","unstructured":"10. Bang YJ, Kim YW, Yang HK, <i>et al<\/i>. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): A phase 3 open-label, randomised controlled trial. Lancet. 2012; 379:315-321.","key":"10","DOI":"10.1016\/S0140-6736(11)61873-4"},{"doi-asserted-by":"crossref","unstructured":"11. Yamada Y, Tahara M, Miya T, Satoh T, Shirao K, Shimada Y, Ohtsu A, Sasaki Y, Tanigawara Y. Phase I\/II study of oxaliplatin with oral S-1 as first-line therapy for patients with metastatic colorectal cancer. Br J Cancer. 2008; 98:1034-1038.","key":"11","DOI":"10.1038\/sj.bjc.6604271"},{"doi-asserted-by":"crossref","unstructured":"12. Koizumi W, Takiuchi H, Yamada Y, Boku N, Fuse N, Muro K, Komatsu Y, Tsuburaya A. Phase II study of oxaliplatin plus S-1 as first-line treatment for advanced gastric cancer (G-SOX study). Ann Oncol. 2010; 21:1001-1005.","key":"12","DOI":"10.1093\/annonc\/mdp464"},{"doi-asserted-by":"crossref","unstructured":"13. Yamada Y, Higuchi K, Nishikawa K,<i> et al.<\/i> Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-na\u00efve patients with advanced gastric cancer. Ann Oncol. 2015; 26:141-148.","key":"13","DOI":"10.1093\/annonc\/mdu472"},{"doi-asserted-by":"crossref","unstructured":"14. Zhang X, Liang H, Li Z, <i>et al.<\/i> Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): An open-label, superiority and non-inferiority, phase 3 randomised controlled trial. Lancet Oncol. 2021; 22:1081-1092.","key":"14","DOI":"10.1016\/S1470-2045(21)00297-7"},{"doi-asserted-by":"crossref","unstructured":"15. Terashima M, Iwasaki Y, Mizusawa J, <i>et al.<\/i> Randomized phase III trial of gastrectomy with or without neoadjuvant S-1 plus cisplatin for type 4 or large type 3 gastric cancer, the short-term safety and surgical results: Japan Clinical Oncology Group Study (JCOG0501). Gastric Cancer. 2019; 22:1044-1052.","key":"15","DOI":"10.1007\/s10120-019-00941-z"},{"unstructured":"16. Japanese Gastric Cancer Association. Japanese Classification of Gastric Carcinoma (The 13<sup>th<\/sup> Edition). Kanehara &amp; Co., Ltd, Tokyo, Japan, 1999.","key":"16"},{"unstructured":"17. Japanese Gastric Cancer Association. Japanese Classification of Gastric Carcinoma (The 14<sup>th<\/sup> Edition). Kanehara &amp; Co., Ltd, Tokyo, Japan, 2010.","key":"17"},{"unstructured":"18. Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2021 (ver. 6). Kanehara &amp; Co., Ltd, Tokyo, Japan, 2021.","key":"18"},{"doi-asserted-by":"crossref","unstructured":"19. Katai H, Ishikawa T, Akazawa K, Fukagawa T, Isobe Y, Miyashiro I, Oda I, Tsujitani S, Ono H, Tanabe S, Nunobe S, Suzuki S, Kakeji Y; Registration Committee of the Japanese Gastric Cancer Association. Optimal extent of lymph node dissection for remnant advanced gastric carcinoma after distal gastrectomy: A retrospective analysis of more than 3000 patients from the nationwide registry of the Japanese Gastric Cancer Association. Gastric Cancer. 2020; 23:1091-1101.","key":"19","DOI":"10.1007\/s10120-020-01081-5"},{"doi-asserted-by":"crossref","unstructured":"20. Cunningham D, Allum WH, Stenning SH, <i>et al. <\/i>Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006; 355:11-20.","key":"20","DOI":"10.1056\/NEJMoa055531"},{"doi-asserted-by":"crossref","unstructured":"21. Al-Batlan SE, Homann N, Pauligk C,<i> et al.<\/i> Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): A randomised, phase 2\/3 trial. Lancet. 2019; 393: 1948-1957.","key":"21","DOI":"10.1016\/S0140-6736(18)32557-1"},{"doi-asserted-by":"crossref","unstructured":"22. Kang YK, Yook JH, Park YK, <i>et al.<\/i> PRODIGY: A phase III study of neoadjuvant docetaxel, oxaliplatin, and S-1 plus surgery and adjuvant S-1 versus surgery and adjuvant S-1 for resectable advanced gastric cancer. J Clin Oncol. 2021; 39:2903-2913.","key":"22","DOI":"10.1200\/JCO.20.02914"},{"doi-asserted-by":"crossref","unstructured":"23. Ito S, Sano T, Mizusawa J, Tokunaga M, Hashimoto T, Imamura H, Teshima S, Nihei K, Yamada M, Choda Y, Imamura K, Hato S, Terashima M, Sasako M. Identifying risk factors of complications following total gastrectomy for gastric cancer: Comparison between splenectomy and spleen-preserving surgery - A supplementary analysis of JCOG0110. Gastric Cancer. 2023; 40:114-120.","key":"23","DOI":"10.1159\/000531192"},{"doi-asserted-by":"crossref","unstructured":"24. Chen M, Liang H, Chen M, Wang M, Lin L, Zhou C, Wei L. Risk factors for surgical site infection in patients with gastric cancer: A meta-analysis. Int Wound J. 2023; 20:3884-3897.","key":"24","DOI":"10.1111\/iwj.14264"},{"doi-asserted-by":"crossref","unstructured":"25. Yamashita K, Kurokawa Y, Yamamoto K, Hirota M, Kawabata R, Mikami J, Masuzawa T, Takiguchi S, Mori M, Doki Y. Risk factors for poor compliance with adjuvant S-1 chemotherapy for gastric cancer: A multicenter retrospective study. Ann Surg Oncol. 2017; 24:2639-2645.","key":"25","DOI":"10.1245\/s10434-017-5923-2"},{"unstructured":"26. Edge SB, Byrd DR, Compton CC, <i>et al.<\/i> AJCC Cancer Staging Handbook. 7th ed. Springer-Verlag, New York. United States of America, 2010.","key":"26"},{"doi-asserted-by":"crossref","unstructured":"27. Sano T, Sasako M, Mizusawa J, Yamamoto S, Katai H, Yoshikawa T, Nashimoto A, Ito S, Kaji M, Imamura H, Fukushima N, Fujitani K; Stomach Cancer Study Group of the Japan Clinical Oncology Group. Randomized controlled trial to evaluate splenectomy in total gastrectomy for proximal gastric carcinoma. Ann Surg. 2017; 265:277-283.","key":"27","DOI":"10.1097\/SLA.0000000000001814"},{"doi-asserted-by":"crossref","unstructured":"28. Bonenkamp JJ, Songun I, Hermans J, <i>et al.<\/i> Randomised comparison of morbidity after D1 and D2 dissection for gastric cancer in 996 Dutch patients. Lancet. 1995; 345:745-748.","key":"28","DOI":"10.1016\/S0140-6736(95)90637-1"},{"doi-asserted-by":"crossref","unstructured":"29. Cushieri A, Fayers P, Fielding J, Craven J, Bancewicz J, Joypaul V, Cook P. Postoperative morbidity and mortality after D1 and D2 resections for gastric cancer: Preliminary results of the MRC randomised controlled surgical trial. The Surgical Cooperative Group. Lancet. 1996; 347:995-999.","key":"29","DOI":"10.1016\/S0140-6736(96)90144-0"},{"doi-asserted-by":"crossref","unstructured":"30. Talaiezadeh AH, Asgari M, Zargar MA. Mortality and morbidity and disease free survival after D1 and D2 gastrectomy for stomach adenocarcinomas. Asian Pac J Cancer Prev. 2015; 16:5253-5256.","key":"30","DOI":"10.7314\/APJCP.2015.16.13.5253"},{"doi-asserted-by":"crossref","unstructured":"31. van de Velde CJ. Current role of surgery and multimodal treatment in localized gastric cancer. Ann Oncol. 2008; 19:v93-v98.","key":"31","DOI":"10.1093\/annonc\/mdn319"},{"doi-asserted-by":"crossref","unstructured":"32. Rausei S, Ruspi L, Rosa F,<i> et al. <\/i>Extended lymphadenectomy in elderly and\/or highly co-morbid gastric cancer patients: A retrospective multicenter study. Eur J Surg Oncol. 2016; 42:1881-1889.","key":"32","DOI":"10.1016\/j.ejso.2016.05.003"},{"doi-asserted-by":"crossref","unstructured":"33. Songun I, Putter H, Kranenbarg EM, Sasako M, van de Velde CJ. Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. Lancet Oncol. 2010; 11:439-449.","key":"33","DOI":"10.1016\/S1470-2045(10)70070-X"},{"doi-asserted-by":"crossref","unstructured":"34. Wu CW, Hsiung CA, Lo SS, Hsieh MC, Chen JH, Li AF, Lui WY, Whang-Peng J. Nodal dissection for patients with gastric cancer: A randomised controlled trial. Lancet Oncol. 2006; 7:309-315.","key":"34","DOI":"10.1016\/S1470-2045(06)70623-4"},{"doi-asserted-by":"crossref","unstructured":"35. Harris A, Butterworth JB, Boshier PR, Mavroveli S, Vadhwana B, Peters CJ, Eom BW, Yeh CC, Mikhail S, Sasako M, Kim YW, Hanna GB. Development of a reliable surgical quality assurance tool for gastrectomy in oncological trials. Gastric Cancer. 2024; 27:876-883.","key":"35","DOI":"10.1007\/s10120-024-01503-8"},{"doi-asserted-by":"crossref","unstructured":"36. Aoyama T, Sato T, Segami K, <i>et al.<\/i> Risk factors for the loss of lean body mass after gastrectomy for gastric cancer. Ann Surg Oncol. 2016; 23:1963-1970.","key":"36","DOI":"10.1245\/s10434-015-5080-4"},{"doi-asserted-by":"crossref","unstructured":"37. Diaz SP, Brouwer MC, van de Beek D. Sex and gender differences in bacterial infections. Infect Immun. 2022; 90:e0028322.","key":"37","DOI":"10.1128\/iai.00283-22"},{"doi-asserted-by":"crossref","unstructured":"38. Imai E, Ueda M, Kanao K, Kubota T, Hasegawa H, Omae K, Kitajima M. Surgical site infection risk factors identified by multivariate analysis for patient undergoing laparoscopic, open colon, and gastric surgery. Am J Infect Control. 2008; 36:727-731.","key":"38","DOI":"10.1016\/j.ajic.2007.12.011"},{"doi-asserted-by":"crossref","unstructured":"39. Ikeda M, Furukawa H, Imamura H, Shimizu J, Ishida H, Masutani S, Tatsuta M, Kawasaki T, Satomi T. Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor agent in animal model and in patients with impaired renal function. Cancer Chemother Pharmacol. 2002; 50:25-32.","key":"39","DOI":"10.1007\/s00280-002-0457-z"},{"doi-asserted-by":"crossref","unstructured":"40. Aoyama T, Yoshikawa T, Hayashi T, Kuwabara H, Mikayama Y, Ogata T, Cho H, Tsuburaya A. Risk factors for 6-month continuation of S-1 adjuvant chemotherapy for gastric cancer. Gastric Cancer. 2013; 16:133-139.","key":"40","DOI":"10.1007\/s10120-012-0158-1"},{"doi-asserted-by":"crossref","unstructured":"41. Peters GJ, Noordhuis P, van Groeningen CJ, Giaccone G, Holwerda U, Voorn D, Schrijvers A, Schornagel JH, Beijnen JH, Fumoleau P, Schellens JH. The effect of food on the pharmacokinetics of S-1 after single oral administration to patients with solid tumors. Clin Cancer Res. 2004; 10:4072-4076.","key":"41","DOI":"10.1158\/1078-0432.CCR-1076-03"},{"doi-asserted-by":"crossref","unstructured":"42. Scheulen ME, Saito K, Hilger RA, Mende B, Zergebel C, Strumberg D. Effect of food and a proton pump inhibitor on the pharmacokinetics of S-1 following oral administration of S-1 in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2012; 69:753-761.","key":"42","DOI":"10.1007\/s00280-011-1761-2"},{"doi-asserted-by":"crossref","unstructured":"43. Yamada Y, Hamaguchi T, Goto M, Muro K, Matsumura Y, Shimada Y, Shirao K, Nagayama S. Plasma concentrations of 5-fluorouracil and F-beta-alanine following oral administration of S-1, a dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine, as compared with protracted venous infusion of 5-fluorouracil. Br J Cancer. 2003; 8:816-820.","key":"43","DOI":"10.1038\/sj.bjc.6601224"},{"doi-asserted-by":"crossref","unstructured":"44. Kim WY, Nakada B, Hirakawa K. Alternative pharmacokinetics of S-1 components, 5-fluorouracil, dihydrofluorouracil and alpha-fluoro-beta-alanine after oral administration of S-1 following total gastrectomy. Cancer Sci. 2007; 98:1604-1608.","key":"44","DOI":"10.1111\/j.1349-7006.2007.00573.x"},{"doi-asserted-by":"crossref","unstructured":"45. Iwasa S, Yamada Y, Fukagawa T, Eguchi Nakajima T, Kato K, Hamaguchi T, Morita S, Saka M, Katai H, Shimada Y. Management of adjuvant S-1 therapy after curative resection of gastric cancer: Dose reduction and treatment schedule modification. Gastric Cancer, 2011; 14:28-34.","key":"45","DOI":"10.1007\/s10120-011-0003-y"},{"doi-asserted-by":"crossref","unstructured":"46. Kampschoer GH, Maruyama K, van de Velde CJ, Sasako M, Kinoshita T, Okabayashi K. Computer analysis in making preoperative decisions: A rational approach to lymph node dissection in gastric cancer patients. Br J Surg. 1989; 76:905-908.","key":"46","DOI":"10.1002\/bjs.1800760910"},{"doi-asserted-by":"crossref","unstructured":"47. Peeters KCMJ, Hundahl SA, Kranenbarg EK, Hartgrink H, van de Velde CJ. Low Maruyama Index surgery for gastric cancer: Blinded reanalysis of the Dutch D1-D2 trial. World J Surg. 2005; 29:1576-1584.","key":"47","DOI":"10.1007\/s00268-005-7907-9"},{"doi-asserted-by":"crossref","unstructured":"48. Hundahl SA, Peeters KC, Kranenbarg EK, Hartgrink H, van de Velde CJ. Improved regional control and survival with &quot;low Maruyama Index&quot; surgery in gastric cancer: autopsy findings from the Dutch D1-D2 Trial. Gastric Cancer. 2007; 10:84-86.","key":"48","DOI":"10.1007\/s10120-007-0426-7"},{"doi-asserted-by":"crossref","unstructured":"49. Kodera Y, Ito S, Mochizuki Y, Ohashi N, Tanaka C, Kobayashi D, Kojima H, Matsui T, Kondo K, Fujiwara M. Long-term follow up of patients who were positive for peritoneal lavage cytology: final report from the CCOG0301 study. Gastric Cancer. 2012; 15:335-337.","key":"49","DOI":"10.1007\/s10120-012-0156-3"},{"doi-asserted-by":"crossref","unstructured":"50. Jamel S, Marker SR, Marlietzis G, Acharya A, Athanasiou T, Hanna GB. Prognostic significance of peritoneal lavage cytology in staging gastric cancer: Systematic review and meta-analysis. Gastric Cancer. 2018; 21:10-18.","key":"50","DOI":"10.1007\/s10120-017-0749-y"}],"container-title":["Global Health &amp; Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ghm\/7\/1\/7_2024.01080\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,8]],"date-time":"2025-03-08T04:11:06Z","timestamp":1741407066000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ghm\/7\/1\/7_2024.01080\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,28]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.35772\/ghm.2024.01080","relation":{},"ISSN":["2434-9186","2434-9194"],"issn-type":[{"type":"print","value":"2434-9186"},{"type":"electronic","value":"2434-9194"}],"subject":[],"published":{"date-parts":[[2025,2,28]]},"article-number":"2024.01080"}}